Research Paper Volume 13, Issue 6 pp 8665—8687

MicroRNA-95-3p serves as a contributor to cisplatin resistance in human gastric cancer cells by targeting EMP1/PI3K/AKT signaling

Down-regulation of miR-95-3p induced slower tumor growth in vivo via decreased expression of oncogenes, inhibiting the EMT process, and down-regulation of drug-resistance proteins. (A) Tumor volume was lower upon treatment with miR-95-3p inhibitor after 21 days of treatment. (B) Tumor volume escalated at a slower rate in the miR-95-3p inhibitor treated group. (C) Lower tumor weight occurred in the miR-95-3p inhibitor-treated group. (D) H&E staining of the tumor. (E) Immunohistochemical staining result of different proteins.

Figure 4. Down-regulation of miR-95-3p induced slower tumor growth in vivo via decreased expression of oncogenes, inhibiting the EMT process, and down-regulation of drug-resistance proteins. (A) Tumor volume was lower upon treatment with miR-95-3p inhibitor after 21 days of treatment. (B) Tumor volume escalated at a slower rate in the miR-95-3p inhibitor treated group. (C) Lower tumor weight occurred in the miR-95-3p inhibitor-treated group. (D) H&E staining of the tumor. (E) Immunohistochemical staining result of different proteins.